The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses

• Published in: Journal of Virology Vol. 90; no. 6; pp. 3086 - 3092
• Main Authors: Pécheur, Eve-Isabelle, Borisevich, Viktoriya, Halfmann, Peter, Morrey, John D., Smee, Donald F., Prichard, Mark, Mire, Chad E., Kawaoka, Yoshihiro, Geisbert, Thomas W., Polyak, Stephen J.
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 15.03.2016
• Subjects: [SDV.CAN]Life Sciences [q-bio]/Cancer; Animals; Antiviral Agents; Antiviral Agents - pharmacology; Cancer; Cell Line; Cells; drug effects; Family; France; Global Health; Growth; Hepatitis; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; immunology; Indoles; Indoles - pharmacology; Infection; Laboratories; Life Sciences; Medicine; Microbial Sensitivity Tests; microbiology; Models, Molecular; Molecular; Molecular Structure; mortality; Pediatrics; pharmacology; Stomatitis; Time; Vaccines and Antiviral Agents; virology; Virus Internalization; Virus Internalization - drug effects; Virus Replication; Virus Replication - drug effects; Viruses; Viruses - drug effects; Pediatrics; Laboratories; Growth; Humans; Viruses; Time; Molecular; Virus Internalization; Microbial Sensitivity Tests; Hepatitis; pharmacology; Molecular Structure; Hepatitis B virus; Indoles; France; immunology; Cell Line; Global Health; microbiology; drug effects; Antiviral Agents; Cells; Medicine; Infection; Stomatitis; Animals; Virus Replication; virology; mortality; Family; Models; Hepatitis C; Hepatitis B

Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report,...